Search company, investor...



Grant | Alive

Total Raised


Last Raised

$220K | 3 yrs ago

About Lipo-ImmunoTech

Lipo-ImmunoTech develops novel adoptive cell therapy technology for cancer. The firm is part of the Medical University of South Carolina.

Headquarters Location

3064 Riverwood Dr

Mount Pleasant, South Carolina, 29466-8170,

United States


Missing: Lipo-ImmunoTech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lipo-ImmunoTech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lipo-ImmunoTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lipo-ImmunoTech is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Lipo-ImmunoTech News

Lipo-ImmunoTech receives grant to develop novel adoptive cell therapy technology for cancer

May 2, 2020

Reviewed by Emily Henderson, B.Sc.May 2 2020 Lipo-ImmunoTech, LLC, a startup based in Charleston, South Carolina, recently received a Phase I Small Business Technology Transfer (STTR) grant of just over $224,000 to continue to develop its novel adoptive cell therapy technology for cancer. The startup is a joint venture involving Shikhar Mehrotra, Ph.D., an immunologist, and Besim Ogretmen, Ph.D., a sphingolipid expert, both of whom are Hollings Cancer Center researchers at the Medical University of South Carolina. Lipo-ImmunoTech also executed an option agreement with the MUSC Foundation for Research Development, which gives it the rights to evaluate the technology further with an eye toward eventually licensing it for commercialization. Adoptive cell therapy is a form of immunotherapy in which a cancer patient's T cells, immune cells that can kill cancer cells, are removed and expanded in the laboratory. The expanded T cells are then infused back into the patient. While adoptive cell therapy is a rapidly growing field and an effective strategy for controlling tumor growth, it does present some challenges. It is very costly. But more importantly, when you isolate the T cells and expand them out, they have to multiply many times. The cells at this point are susceptible to cell death. They are also susceptible to immunosuppression in the tumor microenvironment once they are transferred back into the patient." Shikhar Mehrotra, Ph.D., Immunologist, Hollings Cancer Center, Medical University of South Carolina Mehrotra and Ogretmen are working to address current challenges in adoptive cell therapy by enhancing the viability of expanded T cells and improving their functionality. Their approach is novel in that it factors in the role that lipids, or the molecules that make up cell membranes, play in suppressing the immune system. Related Stories "Lipids have an important role, which is not well studied. They can prevent T cells and other immune cells from functioning properly," explained Mehrotra. "So, we thought that, with our collaboration, we could understand and address these issues to improve the immune response." Ogretmen explained further how better understanding the role of lipids could improve anti-cancer immunotherapy as well as treatments for other diseases. "We formed our small biotech company Lipo-ImmunoTech because mechanistic connections between lipids and immunity provide opportunities to develop novel therapeutic agents and strategies to treat various diseases with unmet clinical needs, such as cancer, neurodegenerative disorders and infections, including COVID-19," said Ogretmen. Mehrotra and Ogretmen are currently investigating the applicability of their new technology to different cancer types. They already have promising data from preclinical studies in prostate cancer, melanoma and lung cancer but are expanding their efforts to other cancers as well. They will use those data to apply for a larger STTR grant early next year. If the data continue to show promise, they hope to take the technology into clinical trial to see whether it outperforms standard immune cell therapies currently in the clinic. Source:

Lipo-ImmunoTech Frequently Asked Questions (FAQ)

  • Where is Lipo-ImmunoTech's headquarters?

    Lipo-ImmunoTech's headquarters is located at 3064 Riverwood Dr, Mount Pleasant.

  • What is Lipo-ImmunoTech's latest funding round?

    Lipo-ImmunoTech's latest funding round is Grant.

  • How much did Lipo-ImmunoTech raise?

    Lipo-ImmunoTech raised a total of $220K.

  • Who are the investors of Lipo-ImmunoTech?

    Investors of Lipo-ImmunoTech include Small Business Innovation Research Awards.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.